SpliceBio Secures $135 Million Series B Financing to Expand Genetic Medicine Pipeline
Deal News | Jun 11, 2025 | PR Newswire Cision SpliceBio
SpliceBio, a clinical-stage genetic medicines company specializing in Protein Splicing technology, has raised $135 million in a Series B financing round. The funding, led by EQT Life Sciences and Sanofi Ventures with participation from Roche Venture Fund and existing investors, will further the clinical development of its lead gene therapy candidate, SB-007, designed to treat Stargardt disease. SB-007 has received clearance from the FDA and UK MHRA for clinical development, marking the first dual AAV gene therapy for Stargardt disease. The financing will also support the development of additional gene therapies across ophthalmology, neurology, and other areas. SpliceBio's proprietary platform addresses the challenge of large gene delivery by utilizing engineered proteins, making a significant potential impact in genetic therapies.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- Spain – SpliceBio is based in Barcelona, Spain, which is relevant as a geographic location for corporate activities.
- United States – The funding involves U.S.-based investors and regulatory clearance from the FDA, highlighting involvement in the U.S. market.
- United Kingdom – The UK Medicines and Healthcare products Regulatory Agency (MHRA) provided clearance for clinical development, indicating UK involvement.
Industry
- Biotechnology – The article deals with SpliceBio, which is a clinical-stage genetic medicines company focused on developing innovative gene therapies.
- Pharmaceuticals – SpliceBio's work on genetic therapies such as SB-007 for Stargardt disease is closely tied to drug development and clinical trials.
- Venture Capital – The financing round was co-led by several venture firms including EQT Life Sciences, a major player in life sciences venture capital.
Financials
- $135 million – The total amount raised in the Series B financing round.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SpliceBio | Target Company | Company | A clinical-stage genetic medicines company pioneering Protein Splicing to develop gene therapies. |
| EQT Life Sciences | Co-Lead Investor | Company | An investment firm focused on life sciences and healthcare. |
| Sanofi Ventures | Co-Lead Investor | Company | The corporate venture capital arm of Sanofi, supporting innovations in biotechnology. |
| Roche Venture Fund | Investor | Company | Corporate venture capital fund of Roche, investing in innovative life science companies. |
| New Enterprise Associates | Existing Investor | Company | A major global venture capital firm that invests in technology and healthcare. |
| UCB Ventures | Existing Investor | Company | Corporate venture arm of biopharmaceutical company UCB, investing in innovative biotech. |
| Ysios Capital | Existing Investor | Company | Spanish venture capital firm focused on the life sciences industry. |
| Gilde Healthcare | Existing Investor | Company | Venture capital fund specialized in healthcare investments. |
| Novartis Venture Fund | Existing Investor | Company | Venture capital fund of Novartis, investing in life sciences. |
| Asabys Partners | Existing Investor | Company | A venture capital firm focusing on investments in early-stage life sciences. |
| Miquel Vila-Perelló, Ph.D. | CEO and Co-Founder | Person | Chief Executive Officer and Co-Founder of SpliceBio. |